Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended July 2, 2010
Business Overview: Greatbatch operates two reportable segments: Greatbatch Medical (components for cardiac rhythm management, neuromodulation, vascular, and orthopaedics) and Electrochem Solutions (electrochemical cells and wireless sensors for industrial and medical applications).
Key Financial Metrics
| Metric | Three Months Ended July 2, 2010 | Six Months Ended July 2, 2010 |
|---|---|---|
| Sales (Revenue) | $140.8 million | $272.8 million |
| Gross Profit | $45.5 million (32.3% margin) | $87.1 million (31.9% margin) |
| Operating Income | $17.3 million (12.3% margin) | $31.3 million (11.5% margin) |
| Net Income | $7.8 million | $13.3 million |
| Diluted EPS | $0.33 | $0.57 |
| Cash Flow from Operations | N/A | $44.2 million |
| Cash and Equivalents (End of Period) | $45.7 million | $45.7 million |
| Total Debt | $263.7 million (Long-term only) | $263.7 million (Long-term only) |
| Working Capital | $162.9 million | $162.9 million |
Material Changes vs. Prior Period
- Revenue: Q2 2010 sales increased 5% year-over-year (YoY) to $140.8 million, driven by growth in Vascular (+20%) and Electrochem (+27%) segments. Six-month sales were flat (-1%) due to inventory adjustments in the prior year.
- Profitability: Operating income increased 39% YoY in Q2 to $17.3 million. This was driven by higher revenue and reduced Selling, General, and Administrative (SG&A) expenses (-8% YoY), partially offset by increased Research, Development, and Engineering (RD&E) costs (+29% YoY).
- Effective Tax Rate: The effective tax rate rose to 35.0% in Q2 2010 compared to 19.4% in Q2 2009. The increase is attributed to the expiration of the U.S. R&D tax credit and the absence of favorable tax audit resolutions present in the prior year.
- Debt Repayment: The company repaid $30.5 million of convertible subordinated notes (CSN I) that were put back to the company in Q2 2010. Additionally, a $20 million principal payment was made on the revolving credit facility in July 2010.
Guidance, Outlook, and Risks
- 2010 Sales Outlook: Management expects full-year 2010 sales growth (constant currency) of 2-5% for CRM/Neuromodulation, 3-7% for Vascular, 3-7% for Orthopaedics, and 0-5% for Electrochem.
- Management Commentary: The CEO noted that while the company is on track to meet guidance, sequential growth may be challenging due to a seasonally slow third quarter, foreign currency headwinds (specifically the Euro), and stabilized customer inventory levels. The company continues to invest in "system-level" product solutions to drive long-term growth.
- Litigation:
- Electrochem Litigation: The company is appealing a $34.5 million jury verdict. A $23 million letter of credit was utilized to bond the appeal. Interest on the judgment accrues at 3.75% annually.
- Pressure Products: A patent infringement action was settled in August 2010 via a cash payment and a covenant not to sue. No further material charges are anticipated.
- Risks: Key risks include dependence on a limited number of customers (top four customers accounted for 61% of sales in the first half of 2010), foreign currency fluctuations, and the impact of U.S. Health Care Reform legislation.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with the top four customers (Boston Scientific, Johnson & Johnson, Medtronic, St. Jude Medical), who represent over 60% of revenue.
- Electrochem Litigation Status: Monitor the progress of the appeal regarding the $34.5 million verdict and the associated interest accruals.
- Foreign Currency Exposure: Assess the impact of the Euro and Mexican Peso exchange rates on Orthopaedics and Mexico-based operations, respectively.
- Debt Covenants: Confirm continued compliance with the Credit Facility covenants (Adjusted EBITDA/Interest Expense ratio and Total Leverage ratio), though the company reported being well within limits as of July 2, 2010.
- RD&E Investment: Evaluate the return on the significant increase in RD&E spending (up 34% YoY for six months) aimed at new system-level products.